We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Yolk, also known as In One Basket Limited, is a pioneering company revolutionizing the food and coffee experience for people on the move. They provide high-quality sandwiches, salads, and improved breakfast options without the premium cost, boasting five successful locations in London and three upcoming openings in the second half of 2023
days to go: TBC investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
No Agent helps landlords to manage and market their properties. No agent have created a much simpler way for landlords to manage the entire rental process which includes marketing, administration, management and 24/7 support for one fixed monthly fee.
days to go: Expired investment: £584,162
Cypher is an education technology company that aims to offer coding education online to children aged 6-12. It asserts that teaching children the tools to think computationally allows them to break down a real-world problem and work out how to fix it. The company teaches its students a variety of coding languages such as Scratch, Python, and JavaScript. Cypher has witnessed a total turnover of £990,000 to date, taught 2000+ online students in less than a year completing over 15,000 hours of teaching, and has created over 100 courses as part of its curriculum. The company has featured in press entities like Forbes, Wired, Harper's Bazaar, BBC News, and New York Times, to name a few. Cypher will use 43% of the investment for hiring key personnel, 42% for platform development, and 15% for customer acquisition costs.
days to go: Expired investment: £290,619
Tribe are a modern, natural nutrition brand, based online and tailored to the customer. The UK sport nutrition market is growing at 23% a year and Tribe have already gained 25,000 members purchasing products from them. All products are formulated for performance and made from the highest natural ingredients. 
days to go: Expired investment: £1,747,470
@pizza is a pizza maker that aims to disrupt the £5.2 billion UK pizza and Italian restaurant market. The company asserts that its modern and fast counter operation can create hand-crafted pizzas in 90 seconds. @pizza is currently ranked the #1 restaurant in Birmingham and #1 pizza restaurant in Edinburgh for over two years with its existing fast-casual restaurants. The company plans to use ‘semi-permanent’ restaurant units situated in high traffic density suburban car parks to drive growth. @pizza believes that these restaurants can cook ten high-quality pizzas a minute, offer contactless takeaway and home delivery in the wake of COVID-19, and incorporate the UK’s first pizza drive-thru business model. The company will use the investment to broaden its customer base, giving consumers the bespoke pizza they want, as well as, how, where and when they want it without significant fixed property costs. It also aims to create franchise opportunities across UK cities.
days to go: Expired investment: £1,257,210
Tart London is a bakery and coffee shop with one location overlooking Clapham Common. They also have their heart set on a second location which they will aim to move into by summer. The use of the proceeds will go towards the rent for the new location as well as getting the premises ready for opening. 
days to go: Expired investment: £229,294
By combining fitness with fashion, art and design, BLOK has become a major competitor of boutique class-based gyms within London. BLOK has appeared on Britain's Next Top Model, as well as working with global stars including Anthony Joshua and Jordan Dunn.

Pitch Rated

60%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £891,790
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph